Docosahexaenoic acid supplementation decreases remnant-like particle-cholesterol and increases the (n-3) index in hypertriglyceridemic men

Journal of Nutrition

Volumn 138, Issue 1, 2008, Pages 30-35

  Kelley, Darshan S ^a   Siegel, David ^b,c   Vemuri, Madhuri ^a   Chung, Gloria H ^d   Mackey, Bruce E ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Martek Biosciences Corporation   (United States)

^e WESTERN REGIONAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CHOLESTEROL; DOCOSAHEXAENOIC ACID; PLACEBO; ANTILIPEMIC AGENT; LIPOPROTEIN; OMEGA 3 FATTY ACID; REMNANT LIKE PARTICLE CHOLESTEROL; REMNANT-LIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID COMPOSITION; MALE; RANDOMIZED CONTROLLED TRIAL; BLOOD; DOUBLE BLIND PROCEDURE; ERYTHROCYTE; MIDDLE AGED;

ADULT; AGED; ANTILIPEMIC AGENTS; CHOLESTEROL; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; ERYTHROCYTES; FATTY ACIDS, OMEGA-3; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 38149006839     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/138.1.30     Document Type: Article

References (47)

1. AHA [monograph on the Internet]. Heart disease and stroke statistics 2007 update. AHA [cited 2007 25 Sept]. Available from:http://www.americanheart.org.
2. Schaefer EJ. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr. 2002;75:191-212.
3. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747-57.
4. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, O'Leary DH, Sadd MF, Tsai MY, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192:211-7.
5. McNamara JR, Shah PK, Nakajima K, Cupples LE, Wilson PWF, Ordovas JM, Schaefer EJ. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001;154:229-36.
6. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-9.
7. Nordestgaard BG, Tybjaerg-Hansen A. IDL, VLDL, chylomicrons and atherosclerosis. Eur J Epidemiol. 1992;8:92-8.
8. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-70.
9. Rupp H, Wagner D, Rupp T, Schulte LM, Maisch B. Risk stratification by the "EPA1DHA level" and the "EPA/AA ratio" focus on antiinflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids. Herz. 2004;29:673-85.
10. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain (n-3) fatty acids and the risk of sudden death. N Engl J Med. 2002;346:1113-8.
11. Harris WS. Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Pharmacol Res. 2007;55:217-23.
12. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39:212-20.
13. von Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2007;10:129-35.
14. von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res. 2007;73:310-5.
15. Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta. 2006;367:36-47.
16. Calder PC. (n-3) Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond). 2004;107:1-11.
17. Breslow JL. (n-3) Fatty acids and cardiovascular disease. Am J Clin Nutr. 2006;83:S1477-82.
18. Buckley R, Shewring B, Turner R, Yaqoob P, Minihane AM. Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr. 2004;92:477-83.
19. Conquer JA, Holub BJ. Supplementation with an algae source of docosahexaenoic acid increases ((n-3)) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J Nutr. 1996;126:3032-9.
20. Nelson GJ, Schmidt PC, Bartolini GL, Kelley DS, Kyle D. The effect of dietary docosahexaenoic acid on plasma lipoproteins and tissue fatty acid composition in humans. Lipids. 1997;32:1137-46.
21. Sanders TA, Gleason K, Griffin B, Miller GJ. Influence of an algal triacylglycerol containing docosahexaenoic acid (22: 6(n-3)) and docosapentaenoic acid (22: 5n-6) on cardiovascular risk factors in healthy men and women. Br J Nutr. 2006;95:525-31.
22. Theobald HE, Chowienczyk PJ, Whittall R, Humphries SE, Sanders TA. LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am J Clin Nutr. 2004;79:558-63.
23. Geppert J, Kraft V, Demmelmair H, Koletzko B. Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial. Br J Nutr. 2006;95:779-86.
24. Maki KC, Van Elswyk ME, McCarthy D, Hess SP, Veith PE, Bell M, Subbaiah P, Davidson MH. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr. 2005;24:189-99.
25. Agren JJ, Hanninen O, Julkunen A, Fogelholm L, Vidgren H, Schwab U, Pynnönen O, Uusitupa M. Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels. Eur J Clin Nutr. 1996;50:765-71.
26. Wu WH, Lu SC, Wang TF, Jou HJ, Wang TA. Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women. Eur J Clin Nutr. 2006;60:386-92.
27. Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. 1997;66:649-59.
28. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr. 2002;76:1007-15.
29. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Best JD, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care. 2003;26:253.
30. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71:1085-94.
31. Hansen JB, Grimsgaard S, Nilsen H, Nordoy A, Bonaa KH. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on fatty acid absorption, incorporation into serum phospholipids and postprandial triglyceridemia. Lipids. 1998;33:131-8.
32. Stark KD, Holub BJ. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr. 2004;79:765-73.
33. Leigh-Firbank EC, Minihane AM, Leake DS, Wright JW, Murphy MC, Griffin BA, Williams CM. Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses. Br J Nutr. 2002;87:435-45.
34. Cazzola R, Russo-Volpe S, Miles EA, Rees D, Banerjee T, Roynette CE, Wells SJ, Goua M, Wahle KW, et al. Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis. 2007;193:159-67.
35. Kelley DS, Siegel D, Vemuri M, Mackey BE. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr. 2007;86:324-33.
36. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-7.
37. Morrison WR, Smith LM. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol. J Lipid Res. 1964;5:600-8.
38. Kelley DS, Bartolini GL, Newman JW, Vemuri M, Mackey BE. Fatty acid composition of liver, adipose tissue, spleen, and heart of mice fed diets containing t10, c12-, and c9, t11-conjugated linoleic acid. Prostaglandins Leukot Essent Fatty Acids. 2006;74:331-8.
39. SAS OnlineDoc. 9.13 ed. Cary (NC): SAS Institute; 2004.
40. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary (NC): SAS Institute; 1996.
41. Vemuri M, Kelley DS. Effect of dietary fatty acids on lipid metabolism. In: Chow CK, editor. Fatty acids in foods and their health implications. 3rd ed. New York: Marcel and Dekker; 2007. p. 589-610.
42. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of (n-3) fatty acids in humans. Am J Clin Nutr. 2006;83:S1467-76.
43. Vidgren HM, Agren JJ, Schwab U, Rissanen T, Hanninen O, Uusitupa MI. Incorporation of (n-3) fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids. 1997;32:697-705.
44. Marangoni F, Angeli MT, Colli S, Eligini S, Tremoli E, Sirtori CR, Galli C. Changes of (n-3) and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout. Biochim Biophys Acta. 1993;1210:55-62.
45. Murphy KJ, Meyer BJ, Mori TA, Burke V, Mansour J, Patch CS, Tapsell LC, Noakes M, Clifton PA, et al. Impact of foods enriched with (n-3) long-chain polyunsaturated fatty acids on erythrocyte (n-3) levels and cardiovascular risk factors. Br J Nutr. 2007;97:749-57.
46. Nakamura N, Hamazaki T, Kobayashi M, Ohta M, Okuda K. Effects of eicosapentaenoic acids on remnant-like particles, cholesterol concentrations and plasma fatty acid composition in patients with diabetes mellitus. In Vivo. 1998;12:311-4.
47. Chan DC, Watts GF, Mori TA, Barrett PH, Redgrave TG, Beilin LJ. Randomized controlled trial of the effect of (n-3) fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr. 2003;77:300-7.